MedTrace Logo

ReZolve2 Clinical Investigation

NCT01845311 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2023-03-29

No results posted yet for this study

Summary

The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.

Conditions

Interventions

DEVICE

ReZolve2 Scaffold

Sponsors & Collaborators

  • REVA Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Alexandre Abizaid, MD · Instituto Dante Pazzanese de Cardiologia

  • David Muller, MD · St Vincent's Hospital, Sydney

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-01-31
Completion
2019-01-31

Countries

  • Australia
  • Brazil
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01845311 on ClinicalTrials.gov